mtor inhibitor

MTI-31 (LXI-15029) is a potent, orally active, and highly selective inhibitor of mTORC1 and mTORC2, exhibiting a Kd of 0.20 nM for mTOR and >5,000-fold selectivity over PIK3CA, PIK3CB, and PIK3G in binding assays, with an IC50 of 39 nM for mTOR in a LANCE assay of mTOR substrate phosphorylation with 100 μM ATP [1].

mTOR inhibitor-3 is a selective mTOR inhibitor (Ki= 1.5 nM). mTOR inhibitor-3 inhibits mTORC1 and mTORC2 in cellular and in vivo experiments.

mTOR inhibitor 9f is a selective mTOR inhibitor with IC50 of 1.25nM and 82nM for mTOR and PI3Kα, respectively.

mTOR inhibitor 9d is a dual inhibitor of the protein kinases mTOR and PI3K with an mTOR IC50 value of 0.31 nm, and can be used for the treatment of leukemia, skin cancer, breast cancer, lung cancer and colon cancer.

mTOR inhibitor 9b is an enzyme inhibitor of protein kinase mTOR he phosphatidylinositol 3-kinase PIK3CA with IC50s of 0.76 nm and 1.262 µM, respectively.mTOR inhibitor 9b possesses anticancer activity and can be used to study leukemia, skin, breast, lung and colon cancers.

mTOR inhibitor 9e is a selective mTOR inhibitor with IC50 of 0.68nM and 1359nM for mTOR and PI3Kα, respectively.

mTOR inhibitor 9a inhibited the growth of human LNCap cells with an ic50 of 80 nm. 1-methyl-3 -{4-[4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)thieno[3,2-d]pyrimidin-2-yl]phenyl}urea may have antitumor activity.

mTOR inhibitor 9c is a selective mTOR inhibitor with IC50 of 0.7nM and 825nM for mTOR and PI3Kα, respectively.

mTOR inhibitor 11 is a useful organic compound for research related to life sciences. The catalog number is T9309 and the CAS number is 1195785-35-3.

mTOR inhibitor 13 is a selective mTOR inhibitor with IC50 of 0.29nM and 119nM for mTOR and PI3Kα, respectively.

HDACs mTOR Inhibitor 1 is a dual HDAC and mammalian target of Rapamycin (mTOR) inhibitor for treating hematologic malignancies, with IC50 values of 0.19 nM, 1.8 nM, 1.2 nM, and >500 nM for HDAC1, HDAC6, mTOR, and PI3Kα, respectively.

mTOR inhibitor-2 is an inhibitor of selective and oral mTOR (IC50 of 7 nM).

PI3K mTOR Inhibitor-2 is a potent pan inhibitor of PI3K and mTOR with IC50s of 3.4, 34, 16.1, and 4.7 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, and mTOR, respectively. PI3K mTOR Inhibitor-2 demonstrates antitumor activity.

PI3K mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K mTOR (PI3Kα PI3Kβ PI3Kδ PI3Kγ mTOR with IC50s of 20 376 204 46 186 nM).

PI3K mTOR Inhibitor-17 (compound 5nh) is a potent inhibitor of PI3K mTOR, exhibiting an inhibitory concentration of 0.45 nM for PI3Kα and 2.9 nM for mTOR. PI3K mTOR Inhibitor-17 plays a significant role in cancer research.

mTOR inhibitor-8 is a potent mTOR inhibitor and autophagy inducer with antiviral and antitumor activity. mTOR inhibitor-8 inhibits the growth of A549 cells, which can be used to study non-small cell lung cancer.

C-4 is a potential ATP-competitive inhibitor of mTOR. C-4 could inhibit cell growth and proliferation.

PI3K mTOR Inhibitor-3 (compound 12) is an imidazoline compound with potent dual inhibition of PI3K and mTOR, exhibiting notable anti-cancer activity [1].

PI3K mTOR Inhibitor-9 (Compound 1) is a potent inhibitor of both mTOR (IC50: 38 nM) and PI3K, including PI3Kα (IC50: 6.6 nM), PI3Kγ (IC50: 6.6 nM), and PI3Kδ (IC50: 0.8 nM).

PI3K mTOR Inhibitor-8 is a dual inhibitor of PI3K (PI3Kα IC50: 0.46 nM) and mTOR (mTOR IC50: 12 nM). PI3K mTOR Inhibitor-8 blocks the cell cycle of HCT-116 cells in G1 S phase and induces apoptosis. apoptosis).

PI3K mTOR Inhibitor-4 is an orally active pan-I PI3K mTOR enzyme inhibitor, acting on PI3Kα (IC50: 0.63 nM), PI3Kγ (IC50: 22 nM), PI3Kδ (IC50: 9.2 nM), and mTOR (IC50: 13.85 nM). PI3K mTOR Inhibitor-4 can be used to study cancer.

PI3K mTOR Inhibitor-7 is a potent dual PI3K mTOR inhibitor. PI3K mTOR Inhibitor-7 is 4.7-fold more potent than gedatolisib, with IC50 values of 1.4 μM and 0.3 μM, respectively. 10 μM of PI3K mTOR Inhibitor-7 is able to significantly inhibit the PI3K Akt mTOR signalling pathway. PI3K mTOR Inhibitor-7 has shown potential for research in cancer diseases.

PI3K mTOR Inhibitor-6 (Compound 19c) is a potent dual PI3K mTOR inhibitor, exhibiting greater stability than gedatolisib in artificial gastric fluid. At 10 μM, PI3K mTOR Inhibitor-6 significantly inhibits the PI3K Akt mTOR signaling pathway and has shown potential for cancer research.

PI3K mTOR Inhibitor-12, a potent and selective orally active inhibitor, exhibits IC50 values of 0.06 nM for PI3Kα and 3.12 nM for mTOR, indicating significant antitumor activity with reduced liver toxicity [1].